Valuation: Orexo AB

Market Cap 455M 46.63M 40.4M 38.13M 34.59M 64.89M 4.47B 65.36M 175M 2.27B 175M 171M 7.21B P/E 2026 *
-1.27x
P/E 2027 * -1.82x
Enterprise Value 350M 35.88M 31.09M 29.34M 26.62M 49.93M 3.44B 50.29M 135M 1.74B 135M 132M 5.55B EV / Sales 2026 *
18.4x
EV / Sales 2027 * 16.9x
Free-Float
78.37%
Yield 2026 *
-
Yield 2027 * -
1 day-1.81%
1 week-11.29%
Current month-16.94%
1 month-14.21%
3 months-38.92%
6 months-44.15%
Current year-56.68%
1 week 13
Extreme 13
14.92
1 month 12.9
Extreme 12.9
16.6
Current year 12.9
Extreme 12.9
36
1 year 12.9
Extreme 12.9
43.4
3 years 9.18
Extreme 9.18
43.4
5 years 8.44
Extreme 8.44
43.4
10 years 8.44
Extreme 8.44
87.9
Manager TitleAgeSince
Chief Executive Officer 54 05/02/2013
Director of Finance/CFO 59 01/09/2022
Chief Tech/Sci/R&D Officer - 01/10/2024
Director TitleAgeSince
Director/Board Member 64 01/01/2002
Director/Board Member 70 11/04/2019
Director/Board Member 62 01/04/2022
Date Insider Type Main position Quantity % Market Cap. Importance
4/9/25 Buy

Chief Executive Officer

6 0.0000%
4/9/25 Free

Chief Executive Officer

1,393 0.0040%
3/9/25 Free 149 0.0004% -
Change 5-day change 1-year change 3-year change Capi.($)
-1.81%-11.29%-50.70%-25.66% 47.86M
+0.70%-2.46%+78.73%+33.79% 355B
-0.68%-3.37%+22.35%-20.78% 66.33B
+0.49%-0.67%+40.95%+165.51% 12.17B
+1.55%-7.41%-9.13%-17.39% 7.47B
-0.38%-8.66%-28.74%-9.08% 4.64B
-0.38%-2.83%-33.92%+12.39% 4.42B
+2.59%-4.57%-33.92%-8.21% 2.86B
+0.72%-0.39%-3.92%+44.35% 2.42B
+1.37%-3.70%-27.42%-25.72% 1.9B
Average +0.44%-4.61%-4.57%+14.92% 45.74B
Weighted average by Cap. +0.51%-4.10%+64.34%+27.44%

Financials

2026 *2027 *
Net sales 19M 1.95M 1.69M 1.59M 1.44M 2.71M 186M 2.73M 7.32M 94.6M 7.31M 7.15M 301M 27M 2.76M 2.4M 2.26M 2.05M 3.85M 265M 3.88M 10.4M 134M 10.38M 10.16M 427M
Net income -375M -38.4M -33.27M -31.4M -28.49M -53.44M -3.68B -53.82M -145M -1.87B -144M -141M -5.94B -
Net Debt -105M -10.75M -9.32M -8.79M -7.98M -14.96M -1.03B -15.07M -40.46M -523M -40.38M -39.49M -1.66B -
Logo Orexo AB
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
Employees
61
Date Price Change Volume
15/09/26 SEK 13.04 -1.81% 22,485
11/09/26 SEK 13.28 -0.90% 35,980
10/09/26 SEK 13.40 +0.75% 75,077
09/09/26 SEK 13.30 -3.48% 25,899
08/09/26 SEK 13.78 -6.26% 67,592
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!